STRYKER CORP

SYK

Held by 4 specialist biotech funds

High Convergence

Share on X

Fund Holdings

4 fund convergence

RTW Investments OrbiMed Advisors Deerfield Management

Position Trend

Feb 13, 2026

$3.0M

1 fund

Feb 17, 2026

$201.6M

3 funds

+6531% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

RTW InvestmentsNEWFeb 17, 2026

Shares: 245,000Value: $86.1M

**Signal Note: RTW Investments enters SYK** Wong's new $86.1M position in Stryker suggests conviction in the orthopedic/surgical device franchise, likely driven by upcoming catalyst visibility in spine or robotics segments where SYK has competitive positioning. This represents a notable allocation for RTW's data-driven approach and suggests quantitative models are flagging favorable risk-reward, though the specific catalyst (product launch, M&A, procedure volume recovery) requires clarification. Monitor for related biotech/medtech plays in Wong's portfolio that may indicate thematic conviction.

OrbiMed AdvisorsNEW

More SYK Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

IRON4 funds ISRG4 funds CELC4 funds NBIX3 funds ARGX3 funds PRAX3 funds ALNY3 funds AXSM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: OrbiMed Initiates $114M Stryker Position OrbiMed's substantial new position in Stryker signals confidence in the orthopedic/surgical device leader's near-term execution and M&A potential. The timing aligns with Stryker's competitive positioning in high-growth segments (robotic-assisted surgery, spine, trauma) and suggests the mega-cap healthcare fund sees undervalued upside relative to peers. No specific catalyst or product launch is publicly disclosed, but the large entry size from a top-tier healthcare investor typically precedes institutional accumulation cycles.